センソ含有製剤「救心」の抗腫瘍作用

概要

論文の詳細を見る
Antitumor effects of "Kyushin" (KY), a medicine containing Senso (Ch'an Su) were studied by using mice bearing Sarcoma 180 ascites tumor or solid tumor. By repeated oral administration of KY, the growth of the ascites was inhibited at a dose of 500 mg/kg/day for 15 days and the growth of the solid tumors at a dose of 1,000 mg/kg/day for 14 days. These inhibitory effects were considered to be caused by bufalin, a constituent of Senso reportedly having a differentiation- and apoptosis-inducing effect on human leukemia cell HL-60. Repeated oral administration of KY at a dose of 500 mg/kg/day, for 5 days, recovered the water-immersion stress-induced decrease of the rate of carbon clearance in mice, which suggests that KY activates the immune response system. This effect may partly contributes to the antitumor effect. Repeated oral administration of KY at a dose of 1,000 mg/kg/day for 18 weeks suppressed the growth of papillomas in the two-stage carcinogenesis induced by 7,12-dimethylbenz [a] anthracene (DMBA) and 12-O-tetradecanoylphorbol-13-acetate (TPA) in mice.
1995-09-20